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Background: Information on the effects of long-term oxygen treatment (LTOT) on blood hemoglobin (Hb) in
severe COPD are limited. The aim was to assess blood Hb values in severe COPD, and investigate the time-course
of both Hb and blood gas changes during a 3-year telemetric LTOT.
Methods: A cohort of 132 severe COPD patients (94 males; 71.4 years ± 8.8 sd), newly admitted to the tele-LTOT
program, was investigated. Subjects were divided according to their original blood Hb: group A: <13 g/dL; group B:
≥13< 15 g/dL; group C: ≥ 5< 16 g/dL; group D: ≥16 g/dL. Blood Hb (g/dL), PaO2 and PaCO2 (mmHg), SaO2 (%),
and BMI were measured at LTOT admission (t0), and at least quarterly over three years (t1-t3). Wilcoxon test was
used to compare t0 vs. t1 values; linear regression to assess a possible Hb-BMI relationship; ANOVA to compare
changes in Hb time-courses over the 3 years.
Results: LTOT induced a systematic increase of PaO2, and changes were significant since the first year (from
52.1 mmHg± 6.6sd to 65.1 mmHg± 8.7 sd, p< 0.001). Changes in SaO2 were quite similar. Comparable and equally
significant trends were seen in all subgroups (p< 0.001). PaCO2 dropped within the first year of LTOT (from
49.4 mmHg± 9.1sd to 45.9 mmHg ±7.5 sd, p< 0.001): the t0-t1 comparison proved significant (p< 0.01) only in
subgroups with the highest basal Hb, who showed a further PaCO2 decline over the remaining two years
(p< 0.001). Hb tended to normalization during LTOT only in subgroups with basal Hb> 15 g/dl (ANOVA p< 0.001);
anemic subjects (Hb< 13 g/dl) ameliorated not significantly in the same period (ANOVA= 0.5). Survival was
independent of the original blood Hb. Anemia and polyglobulia are differently prevalent in COPD, the latter being
the most represented in our cohort. LTOT affected both conditions, but to a different extent and according to
different time-courses. The most striking Hb improvement was in polyglobulic patients in whom also PaO2, PaCO2
and SaO2 dramatically improved. In anemic subjects effects were smaller and slower, oxygenation being equally
ameliorated by LTOT.
Conclusions: LTOT effects on Hb and PaCO2 are regulated by an Hb-dependent gradient which seems
independent of the original impairment of blood gases and of effects on oxygenation.
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Chronic obstructive pulmonary disease (COPD) is cur-
rently defined as characterised by airflow limitation
which is not fully reversible and able to produce sys-
temic consequences (Global Initiative for Chronic Ob-
structive Lung Disease [1]).
Besides its effect on lung function, the chronic impair-
ment of the respiratory system due to COPD has long-
term multi-organ consequences on the bone and liver
metabolism, heart and cardiovascular system, brain, kid-
ney, and skeletal muscles.
Many chronic diseases have been shown to affect
hematopoiesis, and also COPD may be associated to this
kind of disorder which represents further aspects of the
multiple involvement of the disease.
Even though COPD had in the past been commonly
regarded as a determinant of polyglobulia rather than of
anemia [2], it is currently thought that the latter condi-
tion occurs more frequently than expected (in 10-15% of
severe COPD patients) [3], and it is presumed to be
associated with ongoing inflammation, altered erythro-
poietin function, and poor marrow production [4].
There is still limited information concerning the distri-
bution of blood hemoglobin (Hb) concentrations in the
COPD population [3,5,6], although both the direct con-
tribution of anemia in causing breathlessness and the
tendency to a secondary polyglobulia have long been
accepted in severe COPD [2]. On the other hand, limited
information is available concerning the effects of long-
term domiciliary oxygen treatment on Hb and concomi-
tantly on blood gases in these circumstances [7].
The present study aimed to assess the distribution of
blood Hb values in a population of severe COPD
patients with chronic respiratory failure, and to investi-
gate the time course of both Hb and blood gas changes
during a 3-year program of telmonitored long-term oxy-
gen therapy (LTOT).
Methods
A cohort of 132 consecutive non-smoker (87.1% former
smoker), severe COPD patients was studied (94 males;
mean age 71.4 years ± 8.8 sd). All patients had been ad-
mitted as first-time candidates to the domiciliary LTOT
program over the last three years (2008-2010) and were
selected from the dedicated institutional database (ISO
9001-2000 certified since 1999) [8]. In order to avoid
possible bias in the study, both the selection procedures
and the subsequent creation and management of the
data bank were outsourced to IT professionals employed
by a third party, i.e. not working in the Lung Depart-
ment. All COPD patients had a requirement of LTOT
according to our regional guideline; they were managed
according to daily telemonitoring of vital signs (such as
heart rate, SAP, DAP, oxygen saturation (SaO2), oxygenconsumption) and compliance to oxygen therapy, by a
program which has been operating in our Lung Depart-
ment for a a number of years (Contel System, Air
Liquide – VitalAire SA, Paris, France) [9]. From the
point of view of their basic pharmacological respiratory
treatment (directly delivered by the Lung Department
on a regular basis), 96.2% of patients (127/132) were
daily assuming long-acting β2-adrenergics (LABA) and
long-acting anti-cholinergics (LAMA), and 91.7% (121/
132) were also assuming inhaled corticosteroids (ICS).
All patients were also using diuretics (furosemide) and
were equally supplemented with vitamins and other nu-
tritional supports (essential amino acids) [10]. Their ad-
herence to both oxygen (an average consumption of
2.3 L/min liquid oxygen ± 0.8 sd, for at least 17 hours/
day; range 0.5-3.0 L/min) and pharmacological treat-
ments was assessed monthly by professional caregivers,
and defined as very good (>75% of the prescribed doses
in all subjects). The mean% patients’ survival at three
years and the mean prevalence/patient of comorbidities
(e.g. due to cardiovascular, metabolic, renal, gastrointes-
tinal and neurological causes) were also measured.
Blood Hb (g/dL), PaO2 and PaCO2 (mm Hg), SaO2
(%), and BMI were measured in each patient at admis-
sion to the telmonitored LTOT program (t0), and at least
three times/year over the following three years (t1-t3).
Each variable was expressed yearly as mean ± sd of all
measurements performed in the period.
The whole cohort was then divided into four subgroups,
according to the subjects’ original blood Hb: group A: <
13 g/dL; group B: ≥ 13< 15 g/dL; group C: ≥ 15< 16 g/dL;
group D: ≥ 16 g/dL.
For statistical analysis the Wilcoxon test was used to
compare t0 vs. t1 values of all variables, linear regres-
sion was used to compare Hb and BMI values, and
ANOVA to compare changes in Hb time courses of the
entire sample and of each subgroup over the 3-year
period; p< 0.05 was assumed as the minimum level of
significance.
Results
Basal lung function, blood gases, and Hb measured in
the whole population are reported in Table 1, while the
distribution of patients within the four subgroups to-
gether with their corresponding mean blood Hb values
are reported in Table 2. Mean basal Hb level was lower
in females by 0.8 g/dL, and this difference was main-
tained during the entire survey (p = ns). In the entire co-
hort, 18.2% of patients (24/132; 15 males) had a mean
BMI< 23 kg/m2, while clearly pathological Hb levels
were found in only 37.1% of patients (49/132), anemic
subjects being less numerous than polyglobulic subjects
(11.3% vs. 25.8%, respectively). No significant gender dif-
ferences were found.
Table 1 Mean basal values ± sd for lung function, blood
gases, Hb and BMI (n = 132) in the study group
Whole sample Males Females
(n = 132) (n = 94) (n = 38)
FEV1% pred. 35.3 ± 11.8 36.6 ± 16.4 35.7 ± 14.1
FVC% pred. 60.2 ± 10.7 59.2 ± 13.5 62.5 ± 19.3
FEV1/FVC% 58.3 ± 8.1 61.8 ± 7.9 57.1 ± 8.6
pH 7.41 ± 0.05 7.40 ± 0.05 7.41 ± 0.04
PaO2 mm Hg 52.1 ± 6.6 52.2 ± 6.5 51.8 ± 7.1
PaCO2 mm Hg 49.4 ± 9.1 48.9 ± 8.9 50.5 ± 9.5
HCO3 mmol/L 30.5 ± 4.5 30.0 ± 3.9 31.4 ± 5.5
SaO2% 86.3 ± 5.7 86.5 ± 5.7 85.8 ± 6.0
Hb g/dL 15.1 ± 1.9 15.4 ± 2.0 14.5 ± 1.8
BMI 27.4 ± 6.8 27.8 ± 6.9 26.5 ± 6.8
BMI, body mass index; FEV1, forced expiratory volume in 1 second; FVC, forced
vital capacity; Hb, Hemoglobin; PaCO2, partial pressure of arterial carbon
dioxide; PaO2, partial pressure of arterial oxygen; SaO2, oxyhemoglobin
saturation.
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over the 3-year period in the whole cohort and in the four
subgroups with different basal Hb levels are reported in
Figures 1, 2, 3, 4, 5.
LTOT induced a systematic increase of arterial PaO2
in all patients, and changes proved highly significant
already within the first year of LTOT (from 52.1 mm
Hg± 6.6 sd to 65.1 mm Hg±8.7 sd, p< 0.001); then
PaO2 values remained unchanged over the remaining
two years. The corresponding trends in each subgroup
were comparable to that of the whole cohort, and the
comparison between t0 and t1 mean values was equally
statistically significant in all subgroups (p< 0.001)
(Figure 1). A quite similar time course was observed for
SaO2 (Figure 2).
Also the great proportion of changes of arterial PaCO2
measured in the entire cohort of patients occurred
within their first year of LTOT (from 49.4 mm
Hg± 9.1 sd to 45.9 mm Hg± 7.5 sd, p< 0.001). In this
case, the corresponding PaCO2 trends in each subgroup
were very similar to that of the entire cohort, but the
comparison between t0 and t1 mean values proved statis-
tically significant only in group C and D, such as in
those with the highest original Hb values (from 49.8 mmTable 2 Distribution of subjects in the four subgroups
according to their basal hemoglobin (Hb) values, and
corresponding mean Hb values ± sd
Subgroups n (%) Hb (mean ± sd)
A (< 13 g/dL) 15/132 (11.3%) 11.7 g/dL ± 0.9
B (≥ 13 <15 g/dL) 42/132 (31.8%) 14.1 g/dL ± 0.5
C (≥ 15 <16 g/dL) 41/132 (31.1%) 15.4 g/dL ± 0.3
D (≥ 16 g/dL) 34/132 (25.8%) 17.5 g/dL ± 1.3Hg± 10.5 sd to 45.3 mm Hg± 6.2 sd; p< 0.05, and from
49.9 ± 7.9 sd to 45.2 mmHg± 6.9 sd; p< 0.01, respect-
ively). Moreover, subgroup D (i.e. subjects with basal
Hb> 16 g/dL) showed the highest drop in arterial
PaCO2 at t1, and also showed a further progressive
PaCO2 decline towards normal values over the
remaining two years of LTOT (p< 0.001) (Figure 3).
BMI proved significantly related to Hb values in basal
condition (p< 0.03; r = 0.23). The general trends of BMI
for the whole population and the four different sub-
groups persisted without any significant change over the
total 3-year control period (Figure 4).
All changes measured in Hb values are summarized in
Figure 5. Differently from the time course (absolutely
flat) registered in the whole cohort, peculiar trends were
measured in the four subgroups. In particular, Hb values
tended to drop (i.e. to normalize) since the first year
of LTOT in those subgroups originally characterized
by the highest mean Hb values (i.e. > 15 g/dL) (ANOVA
p< 0.001). On the other hand, the anemic subgroup
(Hb< 13 g/dL) showed a progressive but not significant
(ANOVA=0.5) increase of Hb mean values over the 3-
year period; the highest change occurred within the first
year also in these subjects even though the variation
never reached statistical significance (p< 0.08).
Finally, the overall survival was 73.4% at three years:
73.3% in group A; 71.4% in group B; 73.2% in group C,
and 76.5% in group D (p = ns), while the overall preva-
lence of comorbidities was 2.0/patient in the cohort: 2.2/
p in group A; 1.9/p in group B; 2.0/p in group C, and
2.1/p in group D, respectively.
Discussion
Lung function and blood hemoglobin have been investi-
gated extensively in COPD, and continuous long-term
oxygen treatment (>15 hours/day) is generally regarded
as of significant benefit in hypoxemic patients suffering
from COPD [11].
Nevertheless, the true mechanisms underlying the
improved clinical outcomes (e.g. hospitalization rate,
QoL, or survival) during LTOT still have to be clarified,
although it is well known since long ago that long-term
oxygen decreases hematocrit values, pulmonary vascular
resistances, and improves brain performance [12,13].
Anemia and polyglobulia are conditions differently
represented in COPD, the latter being the most preva-
lent in our cohort. Several mechanisms have been sug-
gested to explain the former condition, such as the
shortening of red blood cell lifespan and sequestration
of iron in macrophages, which can lead to the so-called
“anemia of chronic disease” (ACD) [14,15]. ACD repre-
sents a further aspect of the multiple involvement of
COPD and is presently regarded as an immune driven
abnormality that occurs in many inflammatory diseases
p < 0.001
Figure 1 Time course of PaO2 values in the whole cohort and in each subgroup: t test between t0 and t1. Hb, hemoglobin; PaO2, partial
pressure of arterial oxygen.
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morbidity and mortality in chronic renal failure [16,17],
congestive heart failure [18-20], HIV and hepatitis C in-
fection [21-23], digestive disease [3,24], and cancer [25].
Furthermore, anemia is also associated with disability,
impaired physical performance, lower muscle strength in
individuals over 65 yrs of age [6], and reduced health-
related quality of life (HRQL). Recent reports suggest
that anemia is highly prevalent in patients with COPD
and associated with increased mortality [6,26].
Polyglobulia had been traditionally accepted as a sec-
ondary event due to chronic hypoxemia occurring in a
great proportion of COPD patients [2,27]; nevertheless,
it has been supposed that the normal values found in
the majority of COPD patients are the result of a balance
between the trend towards a decreased red cell mass
and an opposite trend towards an increased red cell
mass due to the erythropoietic effect of erythropoietin in
these subjects [28].p<0.001
Figure 2 Time course of PaCO2 values in the whole cohort and in eac
partial pressure of arterial carbon dioxide.Concerning the prevalence of these two conditions,
the anemic condition was found in 11.3% while polyglo-
bulia was found in 25.8% of patients of the present
study, and these findings are in good agreement with the
current literature [3,26,29,30].
LTOT proved to affect both conditions in our cohort,
but to at different extent and according to different time
courses. In particular, the most striking changes in Hb
values were obtained in polyglobulic patients in whom
>90% of the effect (i.e. a decrease) was seen within the
first year of LTOT. In these patients, also PaO2, PaCO2
and SaO2 dramatically improved in the same period;
only PaCO2 showed a further, progressive decrease com-
pared to the original Hb values over the remaining two
years of the survey.
On the contrary, the effect of LTOT on anemic sub-
jects was smaller and much slower. Actually, these
patients were originally characterized by a lower BMI
(25.5 vs. 28.3 and 29.8 kg/m2 of patients with Hb valuesp<0.001
h subgroup: t test between t0 and t1. Hb, hemoglobin; PaCO2,
p<0.001
Figure 3 Time course of SaO2 values in the whole cohort and in each subgroup: t test between t0 and t1. Hb, hemoglobin; SaO2,
oxyhemoglobin saturation.
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couple of years) for an improvement to be seen in both
their Hb and BMI, thus emphasizing the crucial role of
metabolic and nutritional aspects. On the other hand,
the prognostic value of an improved nutritional status
has been demonstrated in severe COPD to be mainly
related to the increase in BMI and other related indices
[31]: BMI values proved directly related to Hb values in
our population during LTOT, particularly in the anemic
subgroup during the third year of the survey (Figures 4
and 5), thus emphasizing the possible role of LTOT in
ameliorating the nutritional status (Hb included) of
anemic subjects.
Moreover, even though oxygenation resulted equally
improved by LTOT in polyglobulic and anaemic
patients, the latter subset of subjects obtained a smaller
and delayed benefit from LTOT in terms of PaCO2
amelioration, likely due to their original lower Hb con-
tent in blood. In other words, the present data suggest
the presence of an Hb-dependent gradient in the LTOT
effect on Hb, which appears to be independent of the ex-
tent of the original impairment of blood gases.
These data tend to confirm those from a previous
study carried out on 13 non selected subjects in whom
no benefits were obtained in terms of changes in Hb andFigure 4 Time course of BMI values in the whole cohort and in eachhematocrit in COPD patients admitted to LTOT for two
years, even though their QoL and both anxiety and de-
pression scores improved significantly [32].
The present data are not in agreement with the
evidence of poorer outcomes and survival at three years
in COPD patients with anemia (hematocrit <35%) when
compared to those with polyglobulia (24% vs. 70%,
respectively) [26]. In particular, in our cohort of 132
severe COPD patients on LTOT, mortality and the
prevalence of comorbidities resulted equally distributed
in polyglobulic and anemic subjects at the end of the 3-year
survey (26.7% vs. 23.5%, and 2.2/patient vs. 2.1/patient,
respectively).
Conclusions
Differently from earlier studies [32], the data of our sur-
vey emphasize the good results of a strict domiciliary
telmonitored protocol for LTOT: Hb values tended to
improve substantially in parallel to blood gases already
from the first year of LTOT in the great majority of se-
vere COPD subjects. Actually, better results were mostly
achieved in polyglobulic subjects who, on the other
hand, represented the most frequent picture of severe
COPD in our cohort. As suggested in previous studies




Figure 5 Time course of Hb values in the whole cohort and in each subgroup: t test between t0 and t1, and anova over time. Hb,
haemoglobin.
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required a longer period of LTOT to obtain smaller
results. While it is plausible that in severe COPD the
anemic condition may represent an independent factor
that can affect the extent and time course of long-term
metabolic outcomes during LTOT, it is however con-
firmed that LTOT plays a crucial role in optimizing
blood gases independently of Hb.
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